Table 1.
Patient characteristics.
| Variable | n (%) or Median (Range) | p | ||
|---|---|---|---|---|
| Total Cohort | De Ritis Ratio Low | De Ritis Ratio High | ||
| Patient count | 125 | 36 | 89 | |
| Age in years | 66 (35–87) | 59 (37–80) | 69 (35–87) | <0.001 |
| Age >66 years | 65 (52%) | 8 (22%) | 57 (64%) | <0.001 |
| Age ≤66 years | 60 (48%) | 28 (78%) | 32 (36%) | |
| Sex | 0.42 | |||
| Men | 79 (63%) | 25 (69%) | 54 (61%) | |
| Women | 46 (37%) | 11 (31%) | 35 (39%) | |
| ECOG score | 0.68 | |||
| 0 | 90 (72%) | 28 (78%) | 62 (70%) | |
| 1 | 33 (26%) | 8 (22%) | 25 (28%) | |
| 2 | 2 (2%) | - | 2 (2%) | |
| Charlson comorbidity index (CCI) | 1 (0–7) | 1 (0–7) | 1 (0–6) | 0.94 |
| Primary location | 0.57 | |||
| Gastrointestinal | 64 (51%) | 22 (61%) | 42 (47%) | |
| Pancreatic | 30 (24%) | 8 (22%) | 22 (25%) | |
| Pulmonal | 11 (9%) | 2 (6%) | 9 (10%) | |
| CUP | 20 (16%) | 4 (11%) | 16 (18%) | |
| Metastatic disease | 124 (99%) | 36 (100%) | 88 (99%) | |
| Metastatic spread | ||||
| Hepatic | 119 (95%) | 32 (89%) | 87 (98%) | 0.057 |
| Lymphonodal | 104 (83%) | 25 (69%) | 79 (89%) | 0.016 |
| Osseous | 51 (41%) | 12 (33%) | 39 (44%) | 0.32 |
| Peritoneal | 24 (19%) | 4 (11%) | 20 (23%) | 0.21 |
| Pulmonal | 6 (5%) | 2 (6%) | 4 (5%) | 1.0 |
| Functional tumor | 42 (34%) | 11 (31%) | 31 (35%) | 0.68 |
| Hedinger syndrome | 5 (4%) | 1 (3%) | 4 (5%) | 1.0 |
| Grading | 0.65 | |||
| G1 | 24 (19%) | 5 (14%) | 19 (21%) | |
| G2 | 95 (76%) | 29 (81%) | 66 (74%) | |
| G3 | 6 (5%) | 2 (6%) | 4 (5%) | |
| Laboratory parameters | ||||
| Chromogranin A in μg/L | 612 (14–601,700) |
355 (14–5283) |
751 (38–601,700) |
0.027 |
| Chromogranin A >204 μg/L | 93 (74%) | 23 (64%) | 70 (79%) | 0.11 |
| Chromogranin A ≤204 μg/L | 32 (26%) | 13 (36%) | 19 (21%) | |
| AST in U/L | 29 (13–139) | 30 (20–84) | 28 (13–139) | 0.34 |
| ALT in U/L | 28 (10–132) | 46 (23–122) | 23 (10–132) | <0.001 |
| De Ritis ratio | 1.09 (0.46–2.87) |
0.74 (0.46–0.93) |
1.23 (0.93–2.87) |
|
| Number of PRRT cycles | 3 (1–6) | 3 (1–5) | 3 (1–6) | 0.084 |
| Previous treatment | ||||
| Operative resection | 78 (62%) | 22 (61%) | 56 (63%) | 0.84 |
| Somatostatin analogues | 87 (70%) | 20 (56%) | 67 (75%) | 0.034 |
| mTOR inhibitor | 24 (19%) | 9 (25%) | 15 (17%) | 0.32 |
| Tyrosine kinase inhibitor | 7 (6%) | 3 (8%) | 4 (5%) | 0.41 |
| Chemotherapy | 38 (30%) | 10 (28%) | 28 (32%) | 0.83 |
| Local ablative therapy | 10 (8%) | 2 (6%) | 8 (9%) | 0.72 |
| Radiation therapy | 6 (5%) | 1 (3%) | 5 (6%) | 0.67 |
| Transcatheter arterial chemoembolization |
9 (7%) | 3 (8%) | 6 (7%) | 0.72 |
Patient characteristics are provided for the total cohort and separated for patients with low or high De Ritis ratio (>0.927), respectively. Both subgroups were compared using Fisher’s exact test or Wilcoxon rank-sum test.